论文部分内容阅读
目的:观察肺炎3号联合阿奇霉素治疗支原体肺炎的临床疗效。方法:82例支原体肺炎患者,随机分为2组各41例。治疗组采用联合肺炎3号联合阿奇霉素治疗;对照组采用单用阿奇霉素治疗。结果:总有效率治疗组92.68%,对照组75.61%;总不良反应率治疗组7.32%,对照组19.51%;2组比较,差异均有统计学意义(P<0.01)。支原体转阴率治疗组95.12%,对照组78.05%,2组比较,差异有统计学意义(P<0.01)。治疗后治疗组与对照组比较CD3+、CD4+、CD4+/CD8+均上升,CD8+降低,2组比较,差异均有统计学意义(P<0.01)。结论:肺炎3号联合阿奇霉素对支原体肺炎的临床治疗效果较单纯使用阿奇霉素好,能够促进支原体转阴,且安全性高,改善患者的免疫功能。
Objective: To observe the clinical efficacy of pneumonia No.3 combined with azithromycin in the treatment of mycoplasma pneumonia. Methods: 82 cases of mycoplasma pneumonia patients were randomly divided into two groups of 41 cases. The treatment group was treated with combination of pneumonia No. 3 and azithromycin; the control group was treated with azithromycin alone. Results: The total effective rate was 92.68% in the treatment group and 75.61% in the control group. The total adverse reaction rate was 7.32% in the treatment group and 19.51% in the control group. There was significant difference between the two groups (P <0.01). Mycoplasma negative rate of 95.12% treatment group, 78.05% in the control group, the two groups, the difference was statistically significant (P <0.01). After treatment, the levels of CD3 +, CD4 +, CD4 + / CD8 + and CD8 + in treatment group and control group were significantly increased (P <0.01). Conclusion: Pneumonia No.3 combined azithromycin has a better curative effect on mycoplasma pneumonia than azithromycin alone, which can promote the negative conversion of mycoplasma, improve the safety and improve the immune function.